Clinical Trial

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

Study acronym: RENEW-IBS-C
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 35 weeks.
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 70 locations 2026-07-08
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07545772
Lead Sponsor Eli Lilly and Company
Conditions Irritable Bowel Syndrome, Constipation
Enrollment 342 participants
Start Date 2026-04-29
Primary Completion 2027-07 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-06